Published in Digestion on July 08, 1999
Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol (2008) 3.37
Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile. J Clin Microbiol (2000) 1.91
GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother (2001) 1.25
Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis (2011) 1.01
Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci (2002) 0.92
Characterization of the Dynamic Germination of Individual Clostridium difficile Spores Using Raman Spectroscopy and Differential Interference Contrast Microscopy. J Bacteriol (2015) 0.88
Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis (2013) 0.87
Pseudomembranous Colitis: Not Always Caused by Clostridium difficile. Case Rep Med (2014) 0.85
A case of pseudomembranous colitis associated with rifampin. Korean J Intern Med (2004) 0.84
The simple predictors of pseudomembranous colitis in patients with hospital-acquired diarrhea: a prospective observational study. Gut Liver (2013) 0.81
Two Novel Myoviruses from the North of Iraq Reveal Insights into Clostridium difficile Phage Diversity and Biology. Viruses (2016) 0.80
Development of pseudomembranous colitis four months after initiation of rifampicin. Case Rep Gastroenterol (2011) 0.80
Risk Factors for the Development of Clostridium difficile-associated Colitis after Colorectal Cancer Surgery. J Korean Soc Coloproctol (2010) 0.79
Stool therapy may become a preferred treatment of recurrent Clostridium difficile? World J Gastroenterol (2013) 0.78
Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway. Front Pharmacol (2016) 0.76
Pseudomembranous colitis. Dis Mon (2015) 0.75
Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis. PLoS One (2017) 0.75
Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis (1997) 2.53
Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA (1996) 2.25
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis (2000) 2.06
Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology (1989) 2.03
Erb/Duchenne's palsy: a consequence of fetal macrosomia and method of delivery. Obstet Gynecol (1986) 1.43
Mucosal biopsy diagnosis of colitis: acute self-limited colitis and idiopathic inflammatory bowel disease. Gastroenterology (1994) 1.41
Review of Clostridium difficile-associated diseases. Am J Infect Control (1986) 1.34
Risk factors for fireworks-related injury in Washington State. JAMA (1984) 1.14
Saccharomyces boulardii is not Saccharomyces cerevisiae. Clin Infect Dis (1996) 1.12
Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis (1993) 1.11
Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther (2000) 1.10
Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol (1989) 1.03
Identification of Clostridium difficile in stool specimens by culture-enhanced gas-liquid chromatography. J Clin Microbiol (1989) 1.03
Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother (1987) 1.00
Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci (1990) 0.92
Characterization of the genetic basis of antibiotic resistance in Clostridium difficile. J Antimicrob Chemother (1994) 0.92
Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res (1993) 0.87
Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. Clin Pharmacol Ther (1993) 0.85
Ciprofloxacin-associated Clostridium difficile disease. Lancet (1995) 0.84
Recurrent Clostridium difficile disease following ciprofloxacin use. Ann Pharmacother (1997) 0.84
Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats. Pharm Res (1991) 0.82
Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther (1999) 0.81
Isolation of Clostridium difficile at a university hospital: a two-year study. Clin Infect Dis (1995) 0.80
Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am (2001) 0.78
Comment on 'The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients'. J Infect (1998) 0.75
Re: probiotics and C difficile diarrhea. Am J Gastroenterol (2000) 0.75